Why Is AVEANNA HEALTHCARE H (AVAH) Stock Up Today?

Aveanna Healthcare (AVAH) shares surged 9.12% to $12.32 in morning trading on Thursday, driven by multiple analyst upgrades and a raised price target from key firms. Two major banks increased their price targets within the last 36 hours, signaling renewed confidence in the company’s outlook. The stock is trading near its 52-week high of $12.52, suggesting a potential breakout from a recent range.

What Happened

UBS raised its price target for AVAH to $13 from $8, while Deutsche Bank increased its target to $16 from $11.50. Both moves came within a short window and contributed to the sharp rise in the stock. Additional upgrades from Raymond James and BMO Capital further reinforced the positive sentiment, with Raymond James setting a $15 price target and maintaining a Strong Buy rating. UBS also maintained a Neutral stance while raising its target. These analyst actions reflect optimism about the company’s fundamentals, including a 20.5% year-to-date revenue increase and a net margin of 10.4%. A correction in the FY2026 revenue forecast to over $2.68 billion also added to the momentum.

What The Data Shows

AVAH is trading at a price-to-earnings ratio of 8.7 and has a market cap of $2.0 billion. The stock has seen significant insider selling in recent weeks, with 10 reported sales totaling $215.6 million. The most recent insider transactions occurred on June 30 and July 2. Despite this, the stock is up sharply, trading near its 52-week high. The session is characterized by strong volume and a clear upward trajectory, with the stock showing signs of momentum.

What To Watch

The stock is approaching its 52-week high and may test resistance at $12.52. Investors should monitor upcoming analyst coverage and any further price target revisions. No earnings date is provided, but continued coverage from major banks could influence the stock’s next move.